Rezolute’s ersodetug clears phase 3 bar in tumor hyperinsulinism
Rezolute has a cleaner regulatory story in tumor hyperinsulinism after its phase 3 Uplift study of ersodetug reached the primary endpoint. The result gives the antibody a much stronger footing in a rare disorder defined by dangerous, persistent hypoglycemia driven by excess insulin production, and it arrives as the company prepares for FDA discussions early next year.
The market reaction was immediate. Rezolute shares opened about 10% higher in premarket trading after the update, reflecting how much weight investors placed on a late-stage win in a field where therapeutic options remain sparse and mechanistically attractive drugs can move quickly from scientific curiosity to regulatory relevance.
A responder threshold built around glucose dependence
Uplift used a clinically direct endpoint: at least nine of 16 patients needed a 50% or greater reduction from baseline in glucose infusion rate. Thirteen patients have now met that responder criterion, which is enough to satisfy the study’s primary endpoint. Twelve patients completely discontinued intravenous glucose, a result that matters at the bedside because the need for continuous glucose support marks the severity of the disorder and the burden of inpatient management.
Three participants are still in the pivotal period, including two who have not yet met the responder threshold. One patient withdrew early and died a week later from cancer progression, a reminder that the trial population is not made up of otherwise healthy volunteers but patients with serious underlying disease and fragile metabolic balance.
The enrollment requirements also reflect the seriousness of the target condition. Participants had to be receiving intravenous glucose infusion or parenteral nutrition for at least seven days before joining the trial. In practical terms, the study was asking whether an antibody can interrupt a pathologic insulin signal strongly enough to reduce or eliminate reliance on continuous glucose replacement.
Why an insulin receptor antibody could matter here
Ersodetug is an antibody that binds allosterically to the insulin receptor. That mechanism is relevant because tumor hyperinsulinism does not simply reflect low blood sugar; it reflects an upstream signaling problem in which excessive insulin activity suppresses hepatic glucose output and drives peripheral glucose uptake. A drug that modulates receptor activity rather than only replacing glucose fits the biology of the disease more closely than supportive care alone.
This is also why the endpoint reads as more than a statistical threshold. A drop in glucose infusion rate suggests the underlying hypoglycemic drive has weakened, not just that clinicians are chasing blood sugars more effectively. When that effect is large enough to let patients come off intravenous glucose entirely, the signal becomes both clinically visible and operationally meaningful for hospitals managing prolonged infusion-dependent patients.
Earlier interim updates had already pointed in this direction. Seven of the first eight enrolled patients responded, which left little room for the remaining cohort to disappoint if the pattern held. Analysts had already described a positive outcome as highly likely, and the final endpoint success now matches that earlier trajectory rather than overturning it.
Safety stayed quiet in a high-need population
No drug-related safety findings were attributed to ersodetug. In a rare-disease program, that sentence carries real weight because efficacy alone is rarely enough to support adoption if treatment adds metabolic instability, infusion complications, or treatment-limiting toxicity. Here, the absence of a drug-related safety signal strengthens the practical case for moving the program forward.
The safety profile also matters because the target population is already medically complicated. Patients dependent on intravenous glucose or parenteral nutrition are often vulnerable to fluid shifts, line-related complications, and prolonged hospitalization. A therapy that lowers the glucose burden without introducing a new set of toxicities has a better chance of being integrated into real-world management, especially when the alternative is ongoing supportive care rather than curative intervention.
FDA discussions now carry more weight for the broader program
Rezolute plans to use the Uplift dataset in talks with the FDA in the first quarter of next year. Those discussions will likely shape not only the path in tumor hyperinsulinism but also the broader regulatory narrative around ersodetug. The company’s congenital hyperinsulinism program is more advanced, yet it lost momentum after its phase 3 trial missed the primary endpoint. The agency has already advised Rezolute to meet with staff before filing in that indication.
Positive data in tumor hyperinsulinism may help restore confidence in the drug’s mechanism of action. The underlying logic is straightforward: if allosteric insulin receptor modulation can reduce severe hypoglycemia in one hyperinsulinemic setting, it may support the biologic plausibility of benefit in another, even if the clinical contexts are not identical. Regulators are unlikely to treat the two programs as interchangeable, but consistency across related disorders can still influence how a development program is interpreted.
The key limitation is also plain. Uplift is a small study, and three participants remain in the pivotal period. The final shape of the dataset still depends on how those remaining cases settle, and the result in tumor hyperinsulinism will not erase the prior miss in congenital hyperinsulinism. What it does provide is a late-stage, disease-specific efficacy signal with no drug-related safety concern attached, which is exactly the sort of evidence a company needs when walking into an FDA meeting with a difficult regulatory history behind it.
For now, the phase 3 win gives ersodetug something it did not have before: a clean, endpoint-driven result in a rare hypoglycemia disorder where every reduction in glucose infusion rate translates into a real clinical change for patients and care teams.